What ApoB is
Apolipoprotein B is the structural protein that wraps around every atherogenic lipoprotein particle in your blood. There's exactly one ApoB molecule per particle. The atherogenic particles include:
- LDL (low-density lipoprotein)
- VLDL (very low-density lipoprotein)
- IDL (intermediate-density lipoprotein)
- Lp(a) (lipoprotein little a)
- Chylomicron remnants
HDL has a different apoprotein (ApoA1), it's not counted in ApoB.
Particle vs cholesterol
The standard lipid panel measures cholesterol carried by these particles. ApoB measures the particles themselves. The distinction matters because:
- Atherosclerosis is driven by particles entering the vessel wall
- What matters is particle number, not cholesterol per particle
- A small dense particle and a large fluffy particle each count as one ApoB but have very different cholesterol content
ApoB-LDL discordance
Patients with metabolic dysfunction (insulin resistance, Type 2 diabetes, metabolic syndrome) often have small dense LDL particles. Their LDL-C may look normal because each particle carries less cholesterol, but ApoB (particle count) is elevated. Their cardiovascular risk is higher than LDL-C suggests.
Conversely, patients with large fluffy LDL may have higher LDL-C with normal ApoB. Their risk is lower than LDL alone suggests.
Why ApoB is better
- Better cardiovascular event predictor than LDL-C in head-to-head studies
- Captures all atherogenic particles in one number
- Resolves LDL-C ambiguity in metabolic syndrome
- More stable across labs and methods
- European guidelines have moved toward ApoB-based targets
Optimal ranges
- Population average: ~95 mg/dL
- Optimal for primary prevention: under 80 mg/dL
- For patients at moderate risk: under 70 mg/dL
- For high-risk patients (existing CVD, diabetes): under 60 mg/dL
- Aggressive prevention: under 50 mg/dL
Treatment targets
Lifestyle and medication interventions that lower ApoB:
- Statins (lower ApoB substantially)
- Ezetimibe
- PCSK9 inhibitors (largest reductions)
- GLP-1 therapy (modest reduction)
- Reduced visceral fat
- Reduced refined carbohydrates
- Regular exercise
The clinical pearl: If you've only checked LDL-C, you may be missing meaningful cardiovascular risk. ApoB should be added to standard lipid panels for adults assessing cardiovascular risk.
Bottom line
ApoB measures atherogenic particle count, the actual driver of atherosclerosis. It's a better cardiovascular risk marker than LDL-C alone. Optimal target depends on risk profile, under 80 mg/dL for primary prevention, lower for higher-risk patients. ApoB should be standard on cardiovascular lab panels.